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Introduction 
Studies of disease outcomes using administrative databases 
have identified a number of problems with the approach that 
suggest the need for a high level of expertise in their conduct. 
This is particularly true in the case of the investigation of the 
role of different insulins and the risk of cancer, which poses 
particular issues addressed below. 
The greatest handicap is that the database has not been 
created specifically to study insulin as a cause of cancer, or 
indeed, cancer as an outcome. Given the relative rarity of some 
forms of cancer, it will frequently be necessary to perform 
simultaneous studies in different regions or countries to obtain 
enough events of interest to perform a meaningful study (in the 
statistical sense). This adds an extra degree of difficulty in that, 
since no two prescription databases are the same, these 
differences need to be taken into account at the start of the 
study. 
All such observational studies must be conducted according to 
good research practice [1] and good epidemiology practice 
guidelines [2], including those specific to pharmaco-
epidemiology [3]. However, there are a number of issues, some 
essential and some desirable, specific to the study of insulin 
and cancer, which must be taken into consideration. 
 
Essential considerations for the study of 
insulin and cancer risk 
Essential considerations for the study of insulin use and cancer 
risk fall under a number of broad headings: epidemiological 
methodology, diabetology, oncology and biostatistics. 
Specific considerations in terms of the epidemiological 
methodology resolve around making sure that the study is 
designed to investigate the hypotheses of interest. Careful 
attention should be paid to issues surrounding confounding 
variables (confounders). These include body mass index 
(BMI), age, socio-economic status and duration and severity of 
diabetes: it would be very difficult to design a good study of 
insulin and cancer risk in the absence of this key information. It 
is also essential to declare the study hypotheses in advance so 
that the study can be designed and adequately powered (in 
terms of sample size) to investigate the hypotheses in a 
meaningful manner. 
The study of diabetes, insulin and cancer is one in which the 
role of the diabetologist is crucial: it is not an area where 
epidemiologists and statisticians can work in isolation from the 
clinical situation. Most meaningful studies will involve 
conducting investigations, which should be as similar in design 
as possible, in different databases in different countries. Thus, it 
is critical to have information from a focus group of 
diabetologists and family doctors to obtain information regarding 
how the various therapies available are prescribed in the 
different health systems. It is critical to separate patients with 
type 1 diabetes from patients with type 2 diabetes in these 
epidemiological studies and to have complete coverage of a 
defined geographic population of all prescriptions issued. A 
complete history from the database of all prescriptions issued to 
the individual patient for their diabetes condition, including oral 
medications, is also essential. 
The best approach, once all patients and their prescriptions 
have been identified, is to link this information with the Cancer 
Registry and the National Death Index (to obtain information on 
patients who have died). The Cancer Registry must be 
population-based and national to allow follow-up of patients who 
may have left the region covered by the prescription register. 
The Cancer Registry should be of good quality (specifically with 
a high level of population coverage and accuracy in terms of the 
diagnosis of cancers found) and cover at least the same 
geographic area as the prescription registry. An initial analysis 
must be run to exclude all patients from the study who have a 
prevalent cancer at the beginning of the defined period of the 
study. 
Recognizing the complicated nature of such studies using 
prescription databases linked to cancer registries, it is vital to 
undertake careful and in-depth statistical analysis. The 
requirement for exploratory data analysis is overwhelming to 
allow the underlying structure of the dataset to become clear. 
Cox regression analyses with and without time-dependent 
covariates represent a sensible approach. Those who changed 
insulin during the study, 'switchers', and those who used more 
than one type of insulin simultaneously pose specific problems, 
which must be addressed. Restriction of the analysis to users of 
one type of insulin during the study period is inappropriate and 
likely to introduce bias. There are outstanding issues 
surrounding how to deal with the entire issue of 'dose', which 
require further exploration by the bio-statistical and 
epidemiological community. 
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 Table 1: Essential check list or evaluation of quality for studies of insulin and cancer risk using prescription databases 
Conclusions 
Analysis of associations between insulin and cancer risk, using 
prescription databases and cancer registries is complicated and 
should only be undertaken with extreme caution. However, even 
though these prescription databases were not established with 
such analyses in mind, it is possible to obtain clear information 
from them if (and only if) the study is designed adequately, key 
data are available and there is good bio-statistical and
epidemiological capability available to analyse and interpret the 
data in a satisfactory manner. 
In Table 1, the essential elements for conducting a meaningful 
study of insulin use and cancer risk, using administrative 
databases, are presented. When evaluating a publication on 
this topic, if the check list results in a number of 'no' responses 
then the value of the study is dubious and the interpretation of 
the findings must be viewed with great caution. 
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